



PRESS RELEASE

TECHNOPHAGE and FACULTY OF VETERINARY MEDICINE, UNIVERSITY OF LISBON Signed a Collaboration Agreement

Lisbon, 4th May 2015 – TECHNOPHAGE, a biopharmaceutical company and FACULTY OF VETERINARY MEDICINE, University of Lisbon, both headquartered in Lisbon, Portugal, have signed a collaboration agreement to develop new therapeutics in diverse areas.

The Faculty of Veterinary Medicine has given important contributions to the development of new diagnostic and therapeutic strategies and innovative biopharmaceutical products. TechnoPhage has also developed expertise in R&D of therapeutic products for several indications.

Today, at the University of Lisbon, the two entities signed a collaboration agreement for the purpose of working together, during the next five years, on the R&D of new therapeutics, based on their mutual and complementary R&D and innovation capabilities.

Miguel Garcia, President and CEO of TechnoPhage said: "This collaboration agreement represents a very important step towards innovation arising from the complementary R&D and innovation capabilities of both the Faculty of Veterinary Medicine and TechnoPhage. TechnoPhage will work enthusiastically with the Faculty of Veterinary Medicine to develop human and animal therapeutics that will benefit patients.

For further information please contact:

Ms. Ana Rolo | Email: arolo@technophage.pt | Phone: +351 217 999 472



About TechnoPhage

TechnoPhage is an innovative biopharmaceutical company engaged in the R&D of new molecules - chemical and biological - in diverse therapeutic areas, such as infection, inflammation & immunology, neurology and metabolic disorders. TechnoPhage's strategy is based on developing new therapeutics in early phases of R&D, with a view to then enters into collaboration deals for pre-clinical and/or clinical development.

TechnoPhage is developing proprietary drug discovery products in either discovery, pre-clinical or clinical stage. The company has several patents in place and successfully developed one of its products into clinical Phase I. TechnoPhage is focused on increasing its portfolio of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across the US, Europe and Asia.

The company's laboratories are located at the Institute of Molecular Medicine (IMM), in Lisbon, under a scientific collaboration protocol signed by both entities. Close proximity to the renowned Santa Maria Hospital and the IMM help facilitate the creation of powerful multidisciplinary teams, essential to the process of translational medicine. Furthermore this proximity helps to facilitate access to the necessary equipment and talent required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.

About Faculty of Veterinary Medicine

The Faculty of Veterinary Medicine (FMV/UL) main activities are education, at both undergraduate and postgraduate level, research and development, and community services within the broad scope of Veterinary Sciences. Research conducted at FMV/UL is pursued at its Centre for Interdisciplinary Research in Animal Health (CIISA). FMV/CIISA comprises a Veterinary Teaching Hospital and modern facilities allocated to research which include 15 well equipped laboratories, several preparatory units, a laboratory animal facility, and a range of multi-use laboratories that promote the sharing of expensive laboratory instrumentation. All laboratories have international ongoing collaborations which further strengths research capacity and facilitate the successful implementation of multidisciplinary research programs.

FMV and CIISA activities are in line with Europe's increasing concerns with animal health related issues that have considerable impact in the global economy and in public health and also with general claims for the development of novel environmentally sustainable systems for animal production and agriculture. High quality multidisciplinary research has been pursued with major impacts on veterinary sciences at social, scientific and economic levels. Contributions to improve animal and human quality of life, under the "One Health" concept, are noticeable through the development of novel strategies for diagnosis and therapeutics, innovative biotechnological products, sustainable production systems and safer animal products.

For further information please contact:

Ms. Ana Rolo | Email: arolo@technophage.pt | Phone: +351 217 999 472